Thus, the use of TrCdc42 and TrRac inhibitors for the treatment of dermatophytosis could potentially cause adverse effects, such as immunosuppression, infections, and acute cardiovascular toxicity, through the inhibition of human Cdc42, Rac, and/or off-targets. The gene discussed is AKT1; the disease is dermatophytosis.